NBIX — Neurocrine Biosciences Inc · P/E 45, rev $1.77B

Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.

Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.

Use this NBIX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NBIX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NBIX SEC filings page. Lician reads the product cache first so this HTML stays unique to Neurocrine Biosciences Inc even when a live quote feed is slow.

Neurocrine Biosciences Inc latest statements (FY2025)

Latest cached year on this hub. Full NBIX income, balance, and cash tables.

  • Revenue$2.86B
  • Net Income$478.6M
  • Total Assets$4.63B
  • Total Debt$0
  • Free Cash Flow$748.7M